Form 4: Enanta Pharmaceuticals CFO Paul J. Mellett Acquires 81,000 Stock Options

Enanta Pharmaceuticals' Chief Financial and Administrative Officer, Paul J. Mellett, was granted 81,000 stock options on November 27, 2024.

Summary

• Paul J. Mellett, the Chief Financial and Administrative Officer of Enanta Pharmaceuticals, acquired 81,000 stock options on November 27, 2024.
• The options have an exercise price of $8.83 per share.
• These options will vest quarterly over four years from the grant date, meaning they will become exercisable in stages.
• The options expire on November 27, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with the long-term performance of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech and pharmaceutical industries.
• The vesting schedule of four years is also typical, designed to incentivize long-term performance and retention.
• Companies like Gilead Sciences, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals also use stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning management's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, insider trading, executive compensation, Enanta Pharmaceuticals, ENTA, Paul J. Mellett